je.st
news
Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research
2016-01-17 15:45:50| Biotech - Topix.net
's stock had its "sell" rating reissued by Zacks Investment Research in a research report issued to clients and investors on Sunday, MarketBeat.Com reports. According to Zacks, "Novo Nordisk's third-quarter 2015 results were strong with revenues increased on the back of robust performance from Victoza and Levemir as well as significant contributions from Tresiba and Saxenda.
Tags: research
rating
sell
investment
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||